Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus from 11 analysts (1 sell, 1 hold, 8 buy, 1 strong buy) with an average 12‑month price target of about $20.56, and several firms (Barclays, Wells Fargo, Oppenheimer) recently raising targets into the high teens/low $20s.
• Relay remains unprofitable (trailing PE -8) but beat the most recent quarter with EPS of ($0.32) vs. ($0.38) expected and revenue of $7.0M; the stock trades near $12.96 (50‑day MA $11.87, 52‑week high $17.32) and analysts forecast -1.51 EPS for the year.
• The CFO sold 1,800 shares under a pre‑arranged Rule 10b5‑1 plan and insiders sold 22,732 shares (~$305k) over the last three months, while institutional investors are reported to own about 96.98% of the stock.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $20.5556.

Several analysts recently weighed in on RLAY shares. Oppenheimer increased their price target on Relay Therapeutics from $14.00 to $18.00 and gave the company an "outperform" rating in a report on Tuesday. JonesTrading initiated coverage on Relay Therapeutics in a research note on Tuesday, April 14th. They set a "hold" rating and a $18.00 price target for the company. Barclays raised their price target on Relay Therapeutics from $17.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 8th. Wells Fargo & Company raised their price target on Relay Therapeutics from $17.00 to $21.00 and gave the stock an "overweight" rating in a research note on Tuesday. Finally, Citizens Jmp raised their price target on Relay Therapeutics from $17.00 to $19.00 and gave the stock a "market outperform" rating in a research note on Tuesday.

Relay Therapeutics Stock Performance

NASDAQ:RLAY opened at $12.96 on Friday. The stock's fifty day moving average is $11.87 and its 200 day moving average is $9.13. Relay Therapeutics has a fifty-two week low of $2.67 and a fifty-two week high of $17.32. The firm has a market capitalization of $2.48 billion, a PE ratio of -8.00 and a beta of 1.57.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.06. The company had revenue of $7.00 million for the quarter, compared to analysts' expectations of $4.34 million. Equities analysts forecast that Relay Therapeutics will post -1.51 EPS for the current year.

Insider Activity

In related news, CFO Thomas Catinazzo sold 1,800 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00. Following the completion of the sale, the chief financial officer directly owned 213,867 shares of the company's stock, valued at approximately $3,208,005. This trade represents a 0.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 22,732 shares of company stock worth $305,048. 4.87% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Torren Management LLC bought a new stake in shares of Relay Therapeutics during the 4th quarter worth approximately $30,000. Smartleaf Asset Management LLC raised its position in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company's stock valued at $37,000 after purchasing an additional 3,287 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Relay Therapeutics during the 4th quarter valued at $46,000. Captrust Financial Advisors bought a new stake in Relay Therapeutics during the 2nd quarter valued at $49,000. Finally, Cerity Partners LLC bought a new stake in Relay Therapeutics during the 2nd quarter valued at $51,000. 96.98% of the stock is owned by institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.